Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Sapanisertib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Pharmacokinetics; Therapeutic Use
- 04 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Nov 2018 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated